SOUTH SAN FRANCISCO, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical
company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it
will report its first quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, May 9,
2017. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00
p.m. PT (5:00 p.m. ET).
Conference Call and Webcast
To access the live conference call, please dial (844) 494-0193 (domestic) or (508) 637-5584 (international) and refer
to the conference ID 9156377.
The webcast may be accessed live on the Investor Relations section of the Company's website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia
website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus
is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from
biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of
therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic
cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an oral small
molecule designed to reduce excessive cardiac muscle contractility leading to HCM and has been evaluated in three Phase 1 clinical
trials. MyoKardia is currently studying MYK-461 in the Phase 2 PIONEER-HCM trial in symptomatic, obstructive HCM (oHCM), a subset
of HCM for which the U.S. Food and Drug Administration (FDA) has granted MYK-461 Orphan Drug Designation. MYK-491, the second
clinical candidate generated by MyoKardia’s product engine, is designed to increase the overall extent of the heart’s contraction
in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy
volunteers; topline data is expected in the third quarter of 2017. A cornerstone of the MyoKardia platform is the Sarcomeric Human
Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and
families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of
data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies.
MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
For more information, please visit www.myokardia.com.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Contact: Steven Cooper Edelman 415-486-3264 steven.cooper@edelman.com
